Time to put an end to the "one size fits all" approach to bisphosphonate use in patients with metastatic breast cancer?

Current Oncology

Volumn 19, Issue 5, 2012, Pages

  Kuchuk, I ^a   Clemons, M ^a   Addison, C ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; ZOLEDRONIC ACID;

BONE DISEASE; BONE METASTASIS; BONE TURNOVER; BREAST METASTASIS; CANCER RISK; CLINICAL PROTOCOL; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FLU LIKE SYNDROME; HUMAN; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; LOW RISK POPULATION; PERSONALIZED MEDICINE; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 84867058288     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1009     Document Type: Editorial

References (6)

1. Costa L. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast 2007;16(suppl 3):S16-20.
2. Bouganim N, Dranitsaris G, Amir E, Clemons M. Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer 2011;19:1687-96.
3. Kuchuk I, Paterson A, Amir E, Clemons M, Bouganim N. Treatment recommendations for the use of bone-targeted agents in 2011-report from the 6th Annual Bone and the Oncologist New Updates meeting. Curr Oncol 2012;19: 364-370.
4. Ali SM, Demers LM, Leitzel K, et al. Baseline serum ntx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 2004;15:455-9.
5. Bouganim N, Hilton JF, Vandermeer L, et al. A multicentre study assessing 12-weekly intravenous bisphosphonate therapy in women with low risk bone metastases from breast cancer-the triumph trial [abstract TPS242]. J Clin Oncol 2011;29:. [Available online at: http://www.asco.org/ascov2/ Meetings/Abstracts?&vmview=abst_detail_view&confID= 102&abstractID=81667; cited July 17, 2012]
6. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, doubleblind study. J Clin Oncol 2010;28:5132-9.